Search

Physician-scientists at Memorial Sloan Kettering Cancer Center (MSK) recently published two papers that advance the science of addressing critical issues with CAR T cell therapy in patients with relapsed or refractory non-Hodgkin lymphomas, profound immune suppression, and predicting the likelihood of treatment failure.

… Tuesday, April 1, 2025 While chimeric antigen receptor (CAR) T cell therapy is an essential therapeutic option for prolonging survival in patients with relapsed or refractory non-Hodgkin lymphomas (NHL), profound immune suppression and predicting the likelihood of treatment failure remain significant

MSK nanotechnology researchers have developed an innovative approach for measuring the permeability of living tumors.

… Tuesday, February 23, 2016 Summary Tumor permeability can be a critical factor in how well a cancer therapy works. MSK researchers developed a method to measure this by creating living tumor spheroids and infiltrating them with very small carbon nanotubes that give off infrared light. The more light

Learn more about how MSK is helping a new generation of patients — including triathlete Derrick Edwin — to navigate work and careers while undergoing treatment for cancer.

… Thursday, April 10, 2025 One November morning in 2021, Derrick Edwin woke with pain in his side — as a triathlete in peak condition, he knew something was off. “Two months before, I had completed an Ironman — that’s a 2.4-mile swim, 112 miles on the bike, followed by a full marathon — and I felt great

Obtenga más información sobre cómo MSK está ayudando a una nueva generación de pacientes, entre ellos el triatleta Derrick Edwin, a gestionar el trabajo y la carrera profesional y el tratamiento contra el cáncer.

… Thursday, April 10, 2025 Una mañana de noviembre de 2021, Derrick Edwin se despertó con dolor en un costado. Como triatleta en óptimas condiciones, sabía que algo andaba mal. “Dos meses antes, había completado un Ironman, eso implica 2.4 millas de natación, 112 millas en bicicleta, seguidas de un maratón

Learn about the latest trends in breast cancer research reported at this year’s SABCS meeting.

… Friday, December 11, 2020 Summary Medical oncologist Komal Jhaveri discusses some of the most important advances in breast cancer treatment and MSK’s leadership role in moving the field forward. Memorial Sloan Kettering medical oncologist Komal Jhaveri played a role in a number of studies presented at

了解在今年 SABCS 会议上报告的乳腺癌研究的最新趋势。

… Friday, December 11, 2020 总结 肿瘤内科医生 Komal Jhaveri 讨论了 乳腺癌 治疗的一些最重要的进展以及 MSK 斯隆如何引领推动该领域的发展。 12 月 8-11 日举行的 2020 年圣安东尼奥乳腺癌研讨会 (SABCS) 上展示了纪念斯隆凯特琳肿瘤内科医生 Komal Jhaveri 参与的多项研究。 今天，Jhaveri 医生将在此与大家分享她对乳腺癌治疗和研究中一些重要趋势的观点。 在今年的 SABCS 上，乳腺癌靶向治疗的重要趋势是什么？ 也许最令人鼓舞的趋势是出现了大量的联合疗法用于治疗内分泌抵抗性乳腺癌。 大多数乳腺癌为雌激素受体 (ER)

Memorial Sloan Kettering and IBM have agreed to collaborate on the development of a powerful tool built upon IBM Watson to provide medical professionals with improved access to comprehensive cancer data and practices.

… Thursday, March 22, 2012 Memorial Sloan Kettering Cancer Center (MSKCC) and IBM (NYSE: IBM) have agreed to collaborate on the development of a powerful tool built upon IBM Watson in order to provide  medical professionals with improved access to current and comprehensive cancer data and practices. The

… Wednesday, January 5, 2022 The oral menin inhibitor SNDX-5613 (Syndax Pharmaceuticals) demonstrated promising antileukemic activity and an acceptable safety profile in patients with heavily pretreated acute leukemias with specific genetic mutations, according to results from phase 1 of the AUGMENT-101

Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer.

… Wednesday, February 15, 2012 Summary Two Memorial Sloan Kettering studies provide new clues about genetic mutations that affect cell behavior and play a role in several types of cancer. Researchers from Memorial Sloan Kettering have published two studies that provide clues about genetic mutations that

An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute of Cancer Research and the Royal Marsden Hospital in the UK as well as other cancer centers around the world published the findings in the May 26, 2011, issue of The New England Journal of Medicine.

… Wednesday, May 25, 2011 An international, multi-center study has found that a recently FDA-approved drug called abiraterone acetate significantly improves overall survival in men with metastatic prostate cancer by more than 34 percent. Researchers at Memorial Sloan Kettering Cancer Center, the Institute